Director at Pulse Biosciences (NASDAQ: PLSE) receives new stock option grants

Rhea-AI Filing Summary

PULSE BIOSCIENCES, INC. director Maria Sainz reported receiving two grants of stock options on June 11, 2026. The awards cover 3,793 and 30,000 options to buy common stock at an exercise price of $26.89 per share and expire on June 11, 2036.

According to the disclosures, 3,793 options vest in equal monthly installments over one year starting July 11, 2026, while 30,000 options vest in equal quarterly installments over one year starting September 5, 2026. These are compensation-related grants, not open‑market stock purchases or sales.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Sainz Maria

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	30,000	$0.00	--
Grant/Award	Stock Option (right to buy)	3,793	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 30,000 shares (Direct, null)

Footnotes (1)

1. The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026. The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026.

Key Figures

Option grant 1 size: 3,793 options Option grant 2 size: 30,000 options Exercise price: $26.89 per share +3 more

6 metrics

Option grant 1 size 3,793 options Stock Option (right to buy) granted June 11, 2026

Option grant 2 size 30,000 options Stock Option (right to buy) granted June 11, 2026

Exercise price $26.89 per share Conversion or exercise price for both option grants

Expiration date June 11, 2036 Options expire if not exercised by this date

Monthly vesting start July 11, 2026 First monthly vesting installment for 3,793-share grant

Quarterly vesting start September 5, 2026 First quarterly vesting installment for 30,000-share grant

Key Terms

Stock Option (right to buy), exercise price, expiration date, vest in equal monthly installments, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 26.8900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-11T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest in equal monthly installments financial

"will vest in equal monthly installments over a one-year period"

vest in equal quarterly installments financial

"will vest in equal quarterly installments over a one-year period"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sainz Maria

(Last) (First) (Middle)

C/O PULSE BIOSCIENCES, INC.

3957 POINT EDEN WAY

(Street)

HAYWARD CALIFORNIA 94545

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PULSE BIOSCIENCES, INC. [ PLSE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$26.89	06/11/2026		A		30,000		(1)	06/11/2036	Common Stock	30,000	$0	30,000	D
Stock Option (right to buy)	$26.89	06/11/2026		A		3,793		(2)	06/11/2036	Common Stock	3,793	$0	3,793	D

Explanation of Responses:

1. The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026.

2. The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026.

	/s/ Kenneth B. Stratton	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Pulse Biosciences (PLSE) disclose in this Form 4 for Maria Sainz?

Pulse Biosciences reported that director Maria Sainz received two grants of stock options on June 11, 2026. The awards are compensation-related and give her the right to buy company common stock in the future at a fixed exercise price.

How many stock options were granted to Maria Sainz at Pulse Biosciences (PLSE)?

Maria Sainz received two option grants: one covering 3,793 stock options and another covering 30,000 stock options. Each grant relates to Pulse Biosciences common stock and is documented as a derivative security with a right to buy shares at a set price.

What is the exercise price and expiration date of Maria Sainz’s options at PLSE?

Both option grants carry an exercise price of $26.89 per share and an expiration date of June 11, 2036. This means she can choose to buy Pulse Biosciences common stock at $26.89 any time before the options expire, subject to vesting.

How do the new Pulse Biosciences (PLSE) options for Maria Sainz vest?

The 3,793-share option grant vests in equal monthly installments over one year starting July 11, 2026. The 30,000-share grant vests in equal quarterly installments over one year starting September 5, 2026, contingent on her continued service at each vesting date.

Is Maria Sainz buying or selling Pulse Biosciences (PLSE) stock in this filing?

The filing shows no open‑market buying or selling of common stock by Maria Sainz. Instead, it reports compensation-related grants of stock options, classified as acquisitions of derivative securities rather than market transactions in existing shares.